Figure 1From: Rationale and design of the RIACT–study: a multi-center placebo controlled double blind study to test the efficacy of RItuximab in Acute Cellular tubulointerstitial rejection with B-cell infiltrates in renal Transplant patients: study protocol for a randomized controlled trial Flowchart of the study design of the RIACT study. Independent from the study protocol, all patients will receive steroid boli for rejection therapy.Back to article page